Source: Applied Genetic Technologies Corporation
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 4:30pm ET in Boston.
AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet age-related macular degeneration and an optogenetics program with Bionic Sight.
A live audio webcast of the presentation can be accessible by visiting www.arminvestorday.com/webcast. A replay will be available on the event website following the event.
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop treatments designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's product pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), both partnered with Biogen, achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet age-related macular degeneration, and our collaborative optogenetics program with Bionic Sight. AGTC’s non-ophthalmology programs include its adrenoleukodystrophy program, also partnered with Biogen, and its otology research program. The otology programs are in pre-clinical development and the company expects to advance several otology product candidates into clinical development in the next few years. AGTC employs a highly-targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need that it believes are clinically feasible and present commercial opportunities. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy treatments.
IR/PR CONTACTS: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 email@example.com or firstname.lastname@example.org CORPORATE CONTACTS: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 email@example.com Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 firstname.lastname@example.org